Abstract CT164: A phase 1 study of abemaciclib in Chinese patients with advanced and/or metastatic cancers
Xichun Hu(Fudan University Shanghai Cancer Center), Sonya C. Chapman(Eli Lilly (United States)), Nong Yang(Central South University), Chunhua Zhou(First Affiliated Hospital of Guangzhou Medical University), Wenhua Li(University of Hong Kong), Weina Shen(Fudan University Shanghai Cancer Center), Rubing Han(Shanghai Medical Information Center), Yi Lu(Shandong Provincial Hospital), Jian Zhang(Fudan University Shanghai Cancer Center), Dongmei Ji(Fudan University Shanghai Cancer Center)
Cited by 0
Related Papers
The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2
|JAMA Oncology|2019|1k
Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non–Small Cell Lung Cancer Patients
|Clinical Cancer Research|2018|551
Perioperative Toripalimab Plus Chemotherapy for Patients With Resectable Non–Small Cell Lung Cancer
|JAMA|2024|359
Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): A multicenter phase 3 study
|Cancer Cell|2021|232
A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor–Positive Breast Cancer
|Clinical Cancer Research|2020|204